viewCapita PLC

Capita lowers profit guidance and warns turnaround plan will take time

Capita reported a 59% drop in underlying pre-tax profit to £80.5mln in the first half

Capita's shares fell 10% in morning trading

Capita PLC (LON:CPI) shares slumped as the outsourcer cut its full-year profit guidance and warned that its turnaround plan would take time to deliver benefits.

Chief executive Jonathan Lewis announced a major overhaul of the business in April, which involves simplifying the business to focus on core areas. The group also launched a £701mln rights issue.

READ: Capita unveils £701mln rights issue as it reports wider annual loss

In the company’s first-half results statement on Wednesday, Lewis said he was making good progress on his strategy and repeated his guidance for a return to growth in 2020.

“It is still early days, but my team and I are very focused and confident in our ability to deliver those commitments,” he said.

Capita reported a 59% drop in underlying pre-tax profit to £80.5mln for the six months ended June 30.  Underlying revenue fell 4% to £1.9bn with declines across all divisions including software, people solutions, customer management, government services, IT services and specialist services.

The order book stood at £7.7bn at the end of the period, down from £8.2bn at December 31, reflecting low levels of bid activity last year and delays in decisions.

For the 2018 financial year, it now expects underlying profits to be between £250mln-£275mln, compared to the £270mln-£300mln it estimated earlier this year.

The group said it was on track to deliver £70mln in cost savings this year and £175mln by 2020. Capita also expects to raise £415mln from the disposal of non-core businesses, including Supplier Assessment Services and ParkingEye.

Shares fell 10% to 145p in morning trading. 

Quick facts: Capita PLC

Price: 38.0647 GBX

Market: LSE
Market Cap: £642.4 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Open Orphan's Cathal Friel hails £4mln contract with top-three global pharma...

Open Orphan PLC's (LON:ORPH) Cathal Friel tells Proactive its subsidiary hVIVO has signed a £4mln contract to conduct a human challenge study for an unnamed top-three global pharma company. The trial will take place at hVIVO’s London quarantine unit and is expected to be completed by the end of...

1 hour, 25 minutes ago

2 min read